Archive for July, 2005
July 30th, 2005. Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation
The offending segment was resected and the ascites was treated with intraperitoneal chemotherapy. Though the patient at present has progression of disease he enjoys a reasonable quality of life after palliation of the ascites and obstruction.
July 28th, 2005. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma
Conclusions: Pleurectomy/decortication with adjuvant radiotherapy is not an effective treatment option for patients with MPM. Our results imply that residual disease cannot be eradicated with external RT with or without brachytherapy and that a more extensive surgery followed by external RT might be required to improve local control and overall survival.
July 25th, 2005. Video-Thoracoscopic Surgical Pleurodesis in the Management of Malignant Pleural Effusion: The Importance of an Early Intervention
9%) underwent further thoracenteses for recurrence of pleural effusion within two months after the procedure. Early use of talc insufflated by video-thoracoscopic surgery is an effective and relatively safe method for treating pleural effusion, and preventing recurrence, in advanced cancer patients.
July 25th, 2005. Case report: Malignant peritoneal mesothelioma in two siblings
Conclusion: This is the first report of two siblings of different gender with malignant peritoneal mesothelioma and only average environmental asbestos exposure. It is highly likely that the family described in this case report has some form of inherited susceptibility to malignancy cancer gene, HLA type, or tumor suppressor gene mutation.
July 22nd, 2005. Malignant Mesothelioma of the Tunica Vaginalis
Conclusions: Malignant mesothelioma of the tunica vaginalis constitutes a rare but often fatal malignancy of the male genitalia. This diagnosis should be suspected in patients exposed to asbestos and presenting with clinical symptoms of either hydrocele or inguinal hernia. Frequent inguinal lymph node involvement indicates a potential role of inguinal lymphadenectomy in the primary treatment.
July 14th, 2005. Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases
Patients may present at different stages, but survival appears to be superior to that of epithelioid mesotheliomas in general. Our study emphasizes the need for better attention to histologic subtypes, particularly in the context of prognostically or therapeutically oriented investigations of this lethal disease.
July 13th, 2005. Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma
Our findings suggest that ErbB1 alone is a therapeutic target for the minority of mesotheliomas and that combining ErbB1 inhibitors with signal transduction inhibitors in mesothelioma will enhance their effectiveness. Furthermore, combinations of growth factor and signal transduction inhibitors may be needed to inhibit the growth of the majority of MPM cell lines, and therefore patients with MPM.
July 5th, 2005. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter
We conclude that a chronic indwelling catheter is a very useful tool in the management of recurrent malignant pleural effusions. Treatment can be accomplished completely at home, whereas complications are rare.
July 5th, 2005. Malignant peritoneal mesothelioma
MPM remains a difficult therapeutic challenge. Thorough cytoreductive surgery is the cornerstone of current treatment while HIIC is a promising strategy in suitable patients.
July 1st, 2005. Treatment planning system evaluation for mesothelioma IMRT
Conclusions: IMRT plans can be calculated for MPM targets by at least three commonly available treatment planning systems. Pinnacle- and Eclipse-based plans seem more efficient, and may be delivered in a shorter time than Corvus-based plans.
July 1st, 2005. The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo
Superior effects could be achieved by performing additional cycles of chemotherapy or adding another drug or radiation for instance. This study shows promising results in the treatment of malignant pleural mesothelioma.
July 1st, 2005. Open-label study of pemetrexed alone or in combination with Cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program
Conclusion: Pemetrexed with or without cisplatin had a favorable safety profile, and the disease control rate (CR + PR + SD) of 71.2% in the subset of patients with peritoneal mesothelioma indicated activity in this patient population.
July 1st, 2005. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma
001) and was an independent prognostic factor in multivariant analysis. Overexpression of COX-2 protein may confer a survival advantage in mesothelioma patients.
July 1st, 2005. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature
Conclusion: WDPM of the peritoneum in women is frequently asymptomatic and associated with an indolent course. Patient outcomes are usually favorable after tumor-debulking surgery without adjuvant therapy.
July 1st, 2005. Prognostic factors in mesothelioma
3] for those in the worst group. The suggestion is that all clinical and biological factors relevant to prognosis should be recorded prospectively in mesothelioma patients selected for clinical trials.
July 1st, 2005. Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma
Experimental work on MPM has shown that tumor selectivity of PDT depend on treatment conditions and can be improved by structural modification and improved targeting of the sensitizers. Refinements of PDT for mesothelioma will depend on a more detailed understanding of the pathways for preferential sensitizer accumulation within the tumor as well as on synergistic effects between PDT and chemotherapeutic agents.
July 1st, 2005. Localized Malignant Mesothelioma
Patients who died had developed local recurrences and metastases, but none had diffuse pleural spread. Localized malignant mesotheliomas should be separated from diffuse malignant mesotheliomas because of their localized presentation, quite different biologic behavior, and far better prognosis.
July 1st, 2005. A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma
Our data indicate that human T lymphocyte samples carry DNA sequences coding for SV40 large T antigen at low prevalence, both in cancer cases and controls. Evidence of cytogenetic damage revealed as micronuclei frequency in mesothelioma cancer patients could be related to exogenous and endogenous cofactors besides asbestos exposure.
July 1st, 2005. Management of malignant pleural effusions
With regard to mesothelioma, recent chemotherapy trials with pemetrexed/cisplatin and raltitrexed/cisplatin are encouraging and appear, for the first time, to offer a small but real survival advantage. Summary: In the authors' opinion, the major developments in the management of malignant effusions during the past year are the development of safer pleurodesis agents and the promise of better combination chemotherapy agents for the treatment of mesothelioma.
|
|  |
